Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record.

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

Wagner, Lars M., McAllister, Nancy, Goldsby, Robert E., Rausen, Aaron R., McNall‐Knapp, René Y., McCarville, M. Beth, Albritton, Karen·2007·Pediatric Blood & Cancer

Abstract

Background: Preclinical models show sequence‐dependent synergy with the combination of temozolomide and irinotecan, and a Phase I trial has demonstrated the combination to be tolerable and active in children with relapsed solid tumors. Because responses were seen in patients with Ewing sarcoma (ES) on that trial, additional patients were treated with this combination following study completion. Procedure: We reviewed data from all ES patients treated with temozolomide and irinotecan at four institutions, including seven patients treated on the above Phase I trial. Results: Sixteen patients received a total of 95 courses, with a median of five courses per patient. All patients had either progressive disease (PD) during initial therapy (n = 5) or relapse within 2 years of diagnosis (n = 11). Twelve patients had metastatic disease at diagnosis, including 5 with bone and/or marrow metastases. Patients received oral temozolomide 100 mg/m 2/day on days 1–5 plus intravenous irinotecan 10–20 mg/m 2/day on days 1–5 and 8–12, with courses repeated every 21–28 days. We observed 1 complete, 3 partial, and 3 minor responses in 14 evaluable patients, with a median duration of response of 30 weeks. Planned 21‐day courses were tolerable and no more toxic than 28‐day courses. Myelosuppression was minimal despite heavy pretreatment. Grade 3–4 diarrhea occurred in 11% of courses and was related to higher irinotecan doses. Over 600 irinotecan doses were administered uneventfully at home. Conclusions: Temozolomide and protracted intravenous irinotecan given in 21‐day courses was tolerable and active in patients with advanced ES. Home administration of irinotecan with temozolomide was safe and is reasonable palliative therapy. A formal Phase II study using a uniform dose and schedule is warranted to better define activity. Pediatr Blood Cancer 2007;48:132–139. © 2006 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.20697

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. 10.1056/NEJMoa020890 · DOI · Paper page
  2. 10.1200/JCO.2003.10.033 · DOI · Paper page
  3. 10.1200/JCO.2000.18.17.3108 · DOI · Paper page
  4. 10.1002/mpo.10240 · DOI · Paper page
  5. 10.1093/annonc/mdg457 · doi:10.1093/annonc/mdg457
  6. 10.1002/mpo.10248 · DOI
  7. 10.1016/S1040-8428(01)00154-8 · DOI
  8. Frohlich B, 1999, High‐dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS, Klin Padiatr, 211, 284
  9. 10.1016/1040-8428(96)00201-6 · doi:10.1016/1040-8428(96)00201-6
  10. Houghton PJ, 2000, Antitumor activity of temozolomide combined with irinotecan is partly independent of O6‐methylguanine‐DNA methyltransferase and mismatch repair phenotypes in xenograft models, Clin Cancer Res, 6, 4110
  11. 10.1007/BF00686188 · DOI · Paper page
  12. 10.1038/bjc.1996.398 · DOI
  13. 10.1200/JCO.1999.17.6.1815 · DOI · Paper page
  14. Patel VJ, 2000, Schedule‐dependent activity of temozolomide plus CPT‐11 against a human central nervous system tumor‐derived xenograft, Clin Cancer Res, 6, 4154
  15. Donafrancesco A, 2003, Temozolomide in resistant or relapsed pediatric solid tumors: A phase II study, Proc Am Soc Clin Oncol, 810a
  16. Pourquier P, 2001, Topoisomerase I‐mediated cytotoxicity of N‐methyl‐N′‐nitro‐N‐nitrosoguanidine: Trapping of topoisomerase I by the O6‐methylguanine, Cancer Res, 61, 53
  17. Stupp R, 2003, Temozolomide and irinotecan for primary brain tumors: A dose escalation study, Proc Am Soc Clin Oncol, 104a
  18. Badruddoja M, Phase 1 study of temozolomide plus irinotean (CPT‐11) in adults with recurrent malignant glioma, Proc Am Soc Clin Oncol, 2003, 102a
  19. 10.1097/01.coc.0000045852.88461.80 · DOI
  20. Jones SF, 2003, Phase I. Trial of irinotecan and temozolomide in patients with solid tumors, Oncology (Huntingt), 17, 41
  21. 10.1158/1078-0432.CCR-03-0175 · DOI
  22. 10.1016/S0031-3955(05)70541-1 · DOI · Paper page
  23. 10.1259/bjr.73.875.11144795 · doi:10.1259/bjr.73.875.11144795
  24. 10.1016/0360-3016(95)00031-S · doi:10.1016/0360-3016(95)00031-s
  25. 10.1093/jnci/93.18.1401 · DOI
  26. 10.1148/radiol.2252011604 · doi:10.1148/radiol.2252011604
  27. 10.1093/jnci/92.3.205 · DOI · Paper page
  28. Furman W, 2003, . Cefixime enables further dose escalation or oral irinotecan in pediatric patients with refractory solid tumors, Proc Am Soc Clin Oncol, 799a
  29. Thompson J, 1997, Efficacy of systemic administration of irinotecan against neuroblastoma xenografts, Clin Cancer Res, 3, 423
  30. Takasuna K, 1996, Involvement of beta‐glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT‐11) in rats, Cancer Res, 56, 3752
  31. 10.1200/JCO.2003.08.175 · DOI
  32. 10.1038/bjc.1998.555 · DOI
  33. Blaney S, 2001, A phase I study of irinotecan in pediatric patients: A pediatric oncology group study, Clin Cancer Res, 7, 32
  34. 10.1097/00043426-200202000-00007 · DOI
  35. 10.1097/00043426-200202000-00009 · doi:10.1097/00043426-200202000-00009
  36. 10.1002/pbc.20107 · doi:10.1002/pbc.20107
  37. 10.1200/JCO.2001.19.15.3463 · DOI · Paper page

Cited by

Metadata

Authors
Wagner, L. M., McAllister, N., Goldsby, R. E., Rausen, A. R., McNall‐Knapp, R. Y., McCarville, M. B., & Albritton, K.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2005-11-29
Volume
48
Issue
2
Pages
132-139
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2129148702
Cited by
197
References
0
FWCI
3.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.